EI
ABOS icon

Ellevest Inc’s Acumen Pharmaceuticals ABOS Stock Holding History

Ellevest Inc’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-257
Closed -$1.39K – 1871
2022
Q4 		$1.39K Hold
257
– – ﹤0.01% 1449
2022
Q3 		$3K Hold
257
– – ﹤0.01% 1252
2022
Q2 		$1K Buy
257
+215
+512% +$808 ﹤0.01% 1199
2022
Q1 		$0 Buy
+42
New +$229 ﹤0.01% 1377

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Ellevest Inc's ABOS Position: Q1 2023 in Review

Ellevest Inc sold out of Acumen Pharmaceuticals (ABOS) in Q1 2023, closing a stake of 257 shares — an estimated $1.39K sold.

Ellevest Inc first reported a position in ABOS in Q1 2022 and held it in 4 quarters. The position peaked at $3K in Q3 2022. 61 funds tracked by Wall St. Rank hold ABOS as of Q1 2023.

  • Ellevest Inc reported no remaining Acumen Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Ellevest Inc sold 257 Acumen Pharmaceuticals shares in Q1 2023, an estimated $1.39K.
  • Ellevest Inc first reported a position in Acumen Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Ellevest Inc's Acumen Pharmaceuticals position peaked at $3K in Q3 2022.
  • 61 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2023.

Based on Ellevest Inc's 13F filing for Q1 2023, filed 4 May 2023.